A study showed that prior hospitalization and the use of multiple medications are risk factors for drug and drug–disease interactions…
Search results for: fracture
Medical Paradoxes in Clinic, Lab Should Encourage Physicians to Reappraise Ideas about Health and Disease
Wash your hands. This most basic tenet of proper hygiene has been drummed into our heads for years. It’s an obvious infection prevention activity, yet for years, compliance among physicians and other caregivers has been lackluster. To rectify this matter, regulatory agencies began auditing hospital staff adherence to this axiom of infection prevention. Not only…
FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling
The makers of FX006, a steroid injection for treating pain in patients with knee osteoarthritis, have submitted a new drug application to the FDA…
Research Underscores Need to Assess Oral Health in Patients with Systemic Sclerosis
Oral health is not frequently considered within the sphere of a rheumatologist’s practice. However, recent results published by the Canadian Scleroderma Research Group (CSRG) point out the importance of assessing oral health in patients with systemic sclerosis (SSc). Result of 3-Year Grant Between 2008 and 2011, 163 patients with SSc and 231 controls were entered…
ACR Opposes DXA Reimbursement Cuts
The Centers for Medicare and Medicaid Services (CMS) plans to significantly reduce reimbursement for dual-energy X-ray absorptiometry (DXA),—used to measure bone density, diagnose osteoporosis and help prevent fractures—performed as a hospital outpatient service in the 2017 Hospital Outpatient Prospective Payment System (HOPPS). If finalized, by 2023 it will cut payment for the DXA testing by 37%….
New Treatment Guidelines to Be Presented at the 2016 ACR/ARHP Annual Meeting
Two sets of guidelines—one on managing anti-rheumatic drugs perioperatively for patients undergoing total hip and knee replacements, and another that updates glucocorticoid-induced osteoporosis prevention and treatment strategies—will be featured in sessions at the 2016 ACR/ARHP Annual Meeting this month. The Sessions Sunday, Nov. 13, 2:30–3:30 p.m.: Glucocorticoid-Induced Osteoporosis Prevention and Treatment: A New ACR Clinical…
Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density
The use of proton pump inhibitors may lead to changes in bone mineral density and an increased risk of developing osteoporosis…
Rheumatology Drug Updates: Abaloparatide Promising for Osteoporosis, Plus Secukinumab for Ankylosing Spondylitis
Abaloparatide for Osteoporosis Abaloparatide is completing Phase III clinical trials for the potential treatment of postmenopausal osteoporosis in women who are at an increased risk of fracture.1 Abaloparatide is a synthetic peptide that engages the parathyroid hormone receptor and has favorable bone building activity. Abaloparatide has completed Phase 3 development for use as a daily…
Rheumatologists on the Move, October 2016
Dr. Amanda King Elected President of Caribbean Association for Rheumatology The Caribbean Association for Rheumatology (CAR) elected Amanda King, MBBS(UWI), MRCP(UK), FRCP(Glas.), president during the 7th Annual CAR Scientific Meeting this summer. This year’s CAR meeting concentrated on education for general practitioners, because there are still some islands without a rheumatologist. She is the only rheumatologist…
Abaloparatide Promising for Osteoporosis; NICE Draft Guidelines Include Secukinumab for Ankylosing Spondylitis
In a clinical trial, subcutaneous abaloparatide has proved effective in treating postmenopausal women with osteoporosis. Also in the U.K., draft guidelines for treating ankylosing spondylitis will recommend the use of secukinumab…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 43
- Next Page »